EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)

NCT07646171 · clinicaltrials.gov ↗

RECRUITING

Status

19

Enrollment

OTHER_GOV

Sponsor class

Conditions

Hormone Receptor Positive Breast Cancer

Interventions

DRUG: Everolimus (Afinitor) tablets with endocrine therapy
PROCEDURE: Blood draw for biomarker and genetic analysis

Sponsor

Tel-Aviv Sourasky Medical Center